Wednesday, October 31, 2012
BioMarin licenses North American rights to rare disease drug, invests $5M in Catalyst Pharmaceutical Partners
Tuesday, October 30, 2012
Monday, October 29, 2012
|Bluebird Bio's David Davidson.|
Sunday, October 28, 2012
Faking out a key player linked to amyotrophic lateral sclerosis could provide a new game plan in drug researchers’ battle against the deadly disorder also known as Lou Gehrig’s disease, according to scientists at the Gladstone Institutes and Stanford University.
Wednesday, October 24, 2012
Tuesday, October 23, 2012
Monday, October 22, 2012
Friday, October 12, 2012
What’s good for Google and a growing number of employers is good for Genentech — and for gay and lesbian employees and their partners. Starting Jan. 1, the South San Francisco-based biotech giant will “gross up” the pay of employees with same-sex partners to cover the taxes that the Internal Revenue Service grabs for company-provided medical benefits to families and the like. The IRS does not tax company benefits received by opposite-sex spouses. But federal tax law does not extend equivalent treatment to same-sex spouses.
Wednesday, October 10, 2012
Private equity firm Longitude Capital closed a fund that will invest in the life sciences after raising $385 million for it. This fund, Longitude Venture Parnters II LP, will invest in drug development and medical technology. The firm had hoped to raise at least $325 million for it.
Tuesday, October 9, 2012
Monday, October 8, 2012
Shinya Yamanaka, the Japanese scientist who reprogrammed mature mouse cells so they could be manipulated to become any type of cell, was named the 2012 winner of the Nobel Prize for physiology or medicine. Yamanaka works part time at the Gladstone Institutes in San Francisco.
Friday, October 5, 2012
Sartorius Stedim SUS Inc., which makes sturdy, IV-like, single-use bags used by drug manufacturers, is closing its Concord plant beginning this month and moving operations to an expanded facility in Puerto Rico. Ninety-one people will lose their jobs in the move, with the first wave expected this month, according to an August letter from the company to Stephen Bailer, executive director of the Workforce Development Board of Contra Costa County. The plant closing process will be completed by the end of April 2013. "We have a great workforce there and we're lucky to have such a committed, long-tenured team," said Sartorius President Mary Lavin in New York. "But we needed to expand."
GlaxoSmithKline has stopped work on a compound from Anacor Pharmaceuticals Inc. after finding resistance among a "small number" of patients in a mid-stage trial in complicated urinary tract infections, Palo Alto-based Anacor said Friday.
A “smart bomb” that targets breast cancer cells while minimizing collateral damage to healthy cells is pushing Genentech Inc. toward its fourth cancer drug approval in 18 months. Trastuzumab emtansine, or T-DM1, which the South San Francisco-based U.S. subsidiary of drug giant Roche AG submitted to the Food and Drug Administration in August, could be approved by the end of February. That timeline is good news for patients, some of whom have pushed the FDA to speed approval of the drug, which piggybacks a chemotherapy agent by ImmunoGen Inc. onto Genentech’s long-running cancer drug Herceptin.
Thursday, October 4, 2012
BioSeek LLC, a South San Francisco biotechnology company, has won a new $46.7 million,contract from the U.S. Environmental Protection Agency to study the potential impacts of environmental chemicals, pesticides, "failed pharmaceuticals, and nanomaterials" on human health. The private company and the EPA separately announced the five-year contract, worth up to $46.7 million, depending on the volume of testing required.
Wednesday, October 3, 2012
|GO-Biz executive director Rish Kajan.|
San Francisco’s surging biotech industry feeds off a network of research institutions, but lease rates and city red tape remain obstacles to growth, according to a report unveiled Wednesday at the San Francisco Chamber of Commerce's “ForecastSF” event. The report, prepared by San Francisco State University associate professor of economics Philip King for the Hospital Council of Northern and Central California, found that hospital and biomedical spending in San Francisco totals $16.7 billion and is responsible for more than 104,000 jobs, or almost one in five jobs in the city. Mayor Ed Lee called the industry a “sleeping giant.” But the giant is restless, according to the report.
Monday, October 1, 2012